These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17443441)

  • 21. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyskinesia-induced postural instability in Parkinson's disease.
    Armand S; Landis T; Sztajzel R; Burkhard PR
    Parkinsonism Relat Disord; 2009 Jun; 15(5):359-64. PubMed ID: 18851925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
    Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy for Parkinson's disease.
    Chen JJ; Swope DM
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):161S-173S. PubMed ID: 18041936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Motor complications in Parkinson disease: clinical manifestations and management.
    Bhidayasiri R; Truong DD
    J Neurol Sci; 2008 Mar; 266(1-2):204-15. PubMed ID: 17897677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease--Part 2: Treatment of motor symptoms.
    Weintraub D; Comella CL; Horn S
    Am J Manag Care; 2008 Mar; 14(2 Suppl):S49-58. PubMed ID: 18402508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.
    Prashanth LK; Fox S; Meissner WG
    Int Rev Neurobiol; 2011; 98():31-54. PubMed ID: 21907082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
    Lane EL; Brundin P; Cenci MA
    Neurobiol Dis; 2009 Jul; 35(1):42-51. PubMed ID: 19361557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of subthalamic nucleus deep brain stimulation on axial motor control and protective arm responses in Parkinson's disease.
    Visser JE; Allum JH; Carpenter MG; Esselink RA; Limousin-Dowsey P; Honegger F; Borm GF; Bloem BR
    Neuroscience; 2008 Dec; 157(4):798-812. PubMed ID: 18952153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
    Tse W
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life in Polish patients with long-lasting Parkinson's disease.
    Zach M; Friedman A; Sławek J; Derejko M
    Mov Disord; 2004 Jun; 19(6):667-72. PubMed ID: 15197705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
    Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
    Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.